Image

Europe Medical cannabis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Europe
  • 350 Pages
  • No of Tables: 364
  • No of Figures: 53

Europe Medical Cannabis Market, By Product (Oil, Dried Medial Cannabis, Medical Cannabis Capsules, Whole Flower, Ground Flower, Vape Pen, Creams & Moisturizer and Others), Source (Synthetic and Natural), Species (Cannabis Indica, Sativa and Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/DELTA-8-Tetrahydrocannabinol and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer's Disease/Migraine, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Settings, Hospital, Rehab Centers and Others), Distribution Channel (B2B and B2C)- Industry Trends and Forecast to 2029.

 

Europe Medical cannabis Market

Market Analysis and Insights

Medical marijuana has also been legalized in other EU member states, most recently in France, Romania, and the Czech Republic. For instance, the use of Sativex has been approved in 17 European countries, nine of which have already made it available.

Europe Medical Cannabis Market

Europe Medical Cannabis Market

Legal cannabis is one of the fastest-growing industries in European states, with major implications for food and beverage, textile, chemical and many other industries. For thousands of years, hemp seeds have been used as a nutritional food. These seeds contain very fewer levels of THC (δ-9-tetrahydrocannabinol), and hence, they are different from medicinal marijuana.

Data Bridge Market Research analyses that the Europe medical cannabis market will grow at a CAGR of 29.5% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Product (Oil, Dried Medial Cannabis, Medical Cannabis Capsules, Whole Flower, Ground Flower, Vape Pen, Creams & Moisturizer and Others), Source (Synthetic and Natural), Species (Cannabis Indica, Sativa and Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/DELTA-8-Tetrahydrocannabinol and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer's Disease/Migraine, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Settings, Hospital, Rehab Centers and Others), Distribution Channel (B2B and B2C)

Countries Covered

Germany, France, U.K., Spain, Italy, Netherlands, Belgium, Russia, Switzerland and Rest of Europe

Market Players Covered

Tilray, Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Aurora Cannabis., Elixinol Global Limited, CANOPY GROWTH CORPORATION, Jazz Pharmaceuticals, Inc., ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc

Market Definition

Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family. For several years, it has been used medicinally and has a wide range of applications in the treatment of various diseases, including chronic pain, cancer, depression, diabetes, arthritis, glaucoma, epilepsy, migraines, AIDS, and Alzheimer’s among others.

 Europe Medical Cannabis Market Dynamics

Drivers

  • Rise in Geriatric Population

The growing geriatric population across the globe is more susceptible to chronic illness, which require more physician visits. The steadily aging population suffers from various health conditions, including diabetes, depression, and dementia, among others. Medical cannabis has the properties to treat these diseases, and therefore, the growing population is playing a significant role.

The use of medical cannabis is more important in the older adult population due to polypharmacy, health literacy, and accessibility of the application process and dispensary locations.

For instance,

  • In September 2021, the scientific research by Lancet stated the elderly population aged over 64 years in Europe had used medical cannabis for the treatment of chronic pain and sleep difficulties, needing requirement of long term medical care services
  • In 2021, according to Knoema, the population aged 65 years and above in France was 21.1%. The population aged 65 years and above in France increased from 13.2% in 1972 to 21.1% in 2021, growing at an average annual rate of 0.97%
  • Rise In incidence of diseases that require the use of cannabis
  • Chronic diseases are common health conditions around the world. Globally, one in three adults suffers from chronic conditions. Neurological diseases have affected the health and quality of life of many citizens. Chronic neurological diseases such as Alzheimer’s disease, cancer, inflammatory bowel disease, and epilepsy can lead to hospitalization, long-term disability, reduced quality of life, and death.
  • Cannabis is a generic term used to denote the several psychoactive preparations of the plant Cannabis sativa. Cannabis has been used for medicinal or recreational purposes. Since cannabinoids react with receptors in the nervous system, researchers believe cannabinoids may be helpful in treating other neurologic conditions as well. Medical cannabis is safe and effective for improving symptoms such as pain, sleep disorders, and anxiety due to chronic diseases in older adults.

For instance,

  • In 2021, the data by Alzheimer's Association stated that more than 1.5 million people in Germany are living with Alzheimer’s disease
  • In 2021, the data by Epilepsia states that Austria (616) reported the maximum number of cases of epilepsy, followed by Denmark (482), Ireland (476), and Romania (414)

As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence and incidence of neurodegenerative diseases would help in finding novel solutions that would aid in more collaborations and partnerships with market players in the Europe region. This signifies the increase in research and development-related investments for the discovery, development, and production of medical cannabis, which is expected to boost market growth.

Europe Medical Cannabis Market

Opportunities

  • Strategic Initiatives By Market Players

The need for medications to treat knee disorders in Europe has increased due to the rise in prevalence and incidence of chronic knee disorders, advanced therapies for knee osteoarthritis and meniscal injuries, and unmet medical needs. The factors (such as rise in incidence, cases of chronic knee disorders, and availability of advanced therapies) enhance the necessity for orthopedic rehabilitation therapy, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

  • In June 2020, Zimmer Biomet received clearance from the Food and Drug Administration (FDA) for ROSA Hip System for Robotically-Assisted Direct Anterior Total Hip Arthroplasty. The clearance received had made the ROSA Hip System available for use by diagnostic centers in Europe and made it clear for post-marketing approval
  • In December 2017, amplitude SURGICAL launched the ACLip, an innovation in anterior cruciate ligament (ACL) reconstruction knee surgery. The ACLip is a knee implant that provides surgeons an enhanced method to perform knee arthroscopy surgeries and is used as an outpatient procedure. The launch had increased the sales and revenue of the knee product segment, and the novel implant was distributed in orthopedic clinics in Europe

Hence, these steps taken by manufacturers are acting as a driver for Europe medical cannabis market. These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.

  • Novel Product Development with Increasing Research and Development (R & D) Activities

Vigorous growth in the demand for cannabis with the legalization has increased the need to come up with better product strains and delivery systems. This has led many companies to conduct research and development activities to check the genetic improvement strategies for cannabis.

For instance,

  1. In 2018, Canopy Growth Corporation in Smiths Falls, which is the largest cannabis company in the world, paid more than USD 300.00 million in cash and shares to acquire Ebbu, which is a small company and is the first to develop platforms for manipulating the cannabis genome with the gene-editing system CRISPR–Cas9
  2. In March 2018, Hydropothecary partnered with Segra in March 2018 to incorporate plant tissue propagation into the cannabis plant production process to help increase the yield of healthy and better variant plants to serve the growing industry for medical and recreational cannabis
  3. Front Range Biosciences, which was founded in 2015, has raised USD 4.60 million up to 2019. The company is currently producing disease-free, and high-yielding strain clones up to 1 million plants in its facility

The companies are extremely focused on developing large-yielding varieties, improved herbicide tolerance, low THC content, and better harvesting and market qualities of cannabis crops. As the strains are improved, this will lead to the production of a better quality of cannabis, and this will create more demand for good quality seeds. Hence, novel product development is expected to act as an opportunity for the Europe medical cannabis market.

Restraints/Challenges

 Long Term and Short Term Side Effects Related to the Use of Cannabis and Cannabis Overuse

Orthopedic specialists observe certain risks while using the implants and consuming the medications. The knee replacement surgeries deliver complications that arise from surgery or a faulty implant. The implant becoming loose is one of the most severe complications after knee surgery, and pain is the most common one. Loosening can cause bone fractures, instability, and serious falls. Almost all serious complications require revision surgery. The risks faced are mechanical risks, knee implant loosening and physical pain.

Marijuana is the second most commonly used psychotropic drug after alcohol. Smoking THC-rich resins, which are extracted from the cannabis plant, is on the rise, and it has caused severe emergency problems for consumers.

THC binds with the specific brain cell receptors to cause several short-term effects such as impaired body movement, altered sense of time, impaired memory, hallucinations, delusions, and psychosis, among many others. It has also been observed in various studies that marijuana affects the process of brain development.

For instance,

  • Researchers at Duke University, New Zealand, observed from a study that the people who have started smoking in their teens lost an average of 8 IQ points between the age of 13 and 38.
  • In 2022, the European Union stated that around 83 million or 28.9 % of adults (aged 15- 64) in the European Union are projected to have used medical cannabis at least once in their lifetime
  • Levels of lifetime use of cannabis differ considerably between countries, ranging from around 4 % of adults in Malta to 45 % in France
  • Medical cannabis is the most commonly used tried medication among (47.6 million males and 30.9 million females)

The consumption of marijuana can cause various life-altering effects. With the increasing awareness of the side effects of marijuana and the increasing health consciousness among people, the use of marijuana can be lowered. This acts as an obstacle for the market. Hence, side effects related to the use of cannabis can act as a challenge for the Europe medical cannabis market to grow in the coming years. Hence, these adverse effects associated with the long-term use of cannabis may hamper the Europe medical cannabis market.

  • Lack of Skilled Personnel

The cannabis industry is not only facing supply shortages, product restrictions, and stringent regulations but also the skilled personnel which is required to run the industry smoothly. The cannabis industry deals with the emerging candidate concerns along with the shortage of skilled personnel. From the stigma of working with previously banned substances to expertise and security, all these challenges are faced by the industry.

As the companies were facing a shortage of personnel, for instance, Green Leaf Medical said that they are in the process of hiring roughly 300 workers for its cultivation and retail operations as the demand is high and more patients are registered every day, but they are lacking the personnel for management.

Europe medical cannabis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Europe medical cannabis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Europe medical cannabis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on the Europe Medical Cannabis Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to rehabilitation clinics will further affect the market. However, the certification received for use of medical cannabis, during the pandemic, showed a positive growth in the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the treatment of neurological diseases during the pandemic.

Recent Development

  • In May 2020, Tilray announced that it had received GMP certification in accordance with European Union standards which allows the facility to manufacture medical cannabis extracts in-house and can export finished medical cannabis products. This helped the company to expand its business.

Europe Medical Cannabis Market Scope

Europe medical cannabis market is segmented on the basis of product, source, species, derivatives, application, and route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Oil
  •  Dried Medical Cannabis
  •  Medical Cannabis Capsules
  •  Vape Pen
  •  Whole Flower
  •  Creams & Moisturizer
  •  Ground Flower
  •  Others

On the basis of product the market is segmented into oil, medical cannabis capsules, whole flower, ground flower, vape pen, dried medical cannabis, creams & moisturizer, and others. Oil is further segmented into by type, by source, and by species.

Source

  • Natural
  • Synthetic

On the basis of source, the market segmented into synthetic and natural.

Species

  • Sativa
  •  Hybrid
  • Cannabis Indica

On the basis of species, the market segmented into sativa, hybrid and cannabis indica.

Derivatives

  • Cannabidiol (CBD)
  •  Tetrahydrocannabinol (THC)/Delta-8-Tetrahydrocannabinol
  •  Others

On the basis of derivatives, the market segmented into cannabidiol (cbd), tetrahydrocannabinol (THC)/delta-8-tetrahydrocannabinol and others.

Application

  • Pain Management
  • Anxiety
  •  Muscle Spasms
  •  Nausea
  •  Appetite Loss
  •  Cancer
  •  Arthritis
  •  Alzheimer's Disease/Migraines
  •  Epilepsy
  •  Depression and Sleep Disorders
  •  Multiple Sclerosis
  •  Autism
  •  Mental Health Conditions
  •  Elevate Mood
  •  Others

On the basis of application, the market segmented into pain management, anxiety, muscle spasms, nausea, appetite loss, cancer, arthritis, Alzheimer’s disease/migraines, epilepsy, depression and sleep disorders, multiple sclerosis, autism, mental health conditions, elevate mood and others.

Route of Administration

  • Oral Solution and Capsules
  •  Smoking
  •  Topicals
  •  Vaporizers
  •  Others

On the basis of application, the market segmented into oral solution and capsules, smoking, topicals, vaporizers and others.

End User

  • Homecare Setting
  •  Hospital
  •  Rehab Centers
  • Pharmaceutical Industry
  •  Research and Development Centers
  •  Others

On the basis of end user, the market is segmented into homecare setting, hospital, rehab centers, pharmaceutical industry, research and development centers and others.

Distribution Channel

  • B2C
  • B2B

Europe Medical Cannabis Market

On the basis of end user, the market is segmented into B2C and B2B.

Europe Medical Cannabis Market Regional Analysis/Insights

Europe medical cannabis market is analyzed and market size insights and trends are provided by country, testing type, type pf tests, site and application, as referenced above.

The countries covered in the Europe medical cannabis market report are Germany, France, U.K., Spain, Italy, Netherlands, Belgium, Russia, Switzerland and Rest of Europe.

Germany is expected to dominate the market due to rise in knee osteoarthritis, rise in knee arthroplasty surgeries and presence of various orthopedic centers in Germany.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are Considered While Providing Forecast Analysis of the country data.

Competitive Landscape and Europe Medical Cannabis Market Share Analysis

Europe medical cannabis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Europe medical cannabis market.

Some of the major players operating in the Europe medical cannabis market are Tilray, Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Aurora Cannabis., CANOPY GROWTH CORPORATION, Jazz Pharmaceuticals, Inc., ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc., among others.

Research Methodology

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE MEDICAL CANNABIS MARKET, BY NUMBER OF PATIENTS, 2020-2029 (IN NUMBER)

TABLE 2 NEUROLOGICAL CONDITIONS FOR WHICH CANNABIS-BASED TREATMENTS HAVE BEEN EMPLOYED

TABLE 3 EUROPE MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 4 EUROPE OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 EUROPE OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 7 EUROPE DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 8 EUROPE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 EUROPE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 10 EUROPE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 11 EUROPE VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 12 EUROPE WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 13 EUROPE GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 18 EUROPE MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 EUROPE PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 21 EUROPE ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 22 EUROPE MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 23 EUROPE NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 24 EUROPE APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 25 EUROPE CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 26 EUROPE ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 27 EUROPE ALZHEIMER'S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 28 EUROPE EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 29 EUROPE DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 30 EUROPE MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 31 EUROPE AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 32 EUROPE MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 EUROPE MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 34 EUROPE ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 35 EUROPE MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 37 EUROPE MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 38 EUROPE B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 39 EUROPE MEDICAL CANNABIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 40 GERMANY MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 41 GERMANY OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 GERMANY OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 43 GERMANY OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 44 GERMANY DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 45 GERMANY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 GERMANY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 47 GERMANY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 48 GERMANY VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 49 GERMANY WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 50 GERMANY GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 51 GERMANY MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 52 GERMANY SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 GERMANY MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 54 GERMANY MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 55 GERMANY MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 GERMANY PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 GERMANY PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 58 GERMANY ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 59 GERMANY MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 60 GERMANY NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 61 GERMANY APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 62 GERMANY CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 63 GERMANY ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 64 GERMANY ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 65 GERMANY EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 66 GERMANY DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 67 GERMANY MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 68 GERMANY AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 69 GERMANY MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 70 GERMANY MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 71 GERMANY ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 72 GERMANY MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 73 GERMANY MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 GERMANY MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 GERMANY B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 76 U.K. MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 77 U.K. OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 U.K. OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 79 U.K. OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 80 U.K. DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 81 U.K. MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 U.K. MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 83 U.K. MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 84 U.K. VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 85 U.K. WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 86 U.K. GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 87 U.K. MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 88 U.K. SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 U.K. MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 90 U.K. MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 91 U.K. MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 92 U.K. PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 U.K. PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 94 U.K. ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 95 U.K. MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 96 U.K. NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 97 U.K. APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 98 U.K. CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 99 U.K. ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 100 U.K. ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 101 U.K. EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 102 U.K. DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 103 U.K. MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 104 U.K. AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 105 U.K. MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 U.K. MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 107 U.K. ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 108 U.K. MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 109 U.K. MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 110 U.K. MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 U.K. B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 ITALY MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 113 ITALY OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 ITALY OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 115 ITALY OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 116 ITALY DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 117 ITALY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 ITALY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 119 ITALY MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 120 ITALY VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 121 ITALY WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 122 ITALY GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 123 ITALY MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 124 ITALY SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 ITALY MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 126 ITALY MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 127 ITALY MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 128 ITALY PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 ITALY PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 130 ITALY ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 131 ITALY MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 132 ITALY NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 133 ITALY APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 134 ITALY CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 135 ITALY ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 136 ITALY ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 137 ITALY EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 138 ITALY DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 139 ITALY MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 140 ITALY AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 141 ITALY MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 ITALY MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 143 ITALY ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 144 ITALY MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 145 ITALY MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 146 ITALY MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 147 ITALY B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 148 NETHERLANDS MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 149 NETHERLANDS OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 NETHERLANDS OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 151 NETHERLANDS OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 152 NETHERLANDS DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 153 NETHERLANDS MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 154 NETHERLANDS MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 155 NETHERLANDS MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 156 NETHERLANDS VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 157 NETHERLANDS WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 158 NETHERLANDS GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 159 NETHERLANDS MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 160 NETHERLANDS SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 NETHERLANDS MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 162 NETHERLANDS MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 163 NETHERLANDS MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 164 NETHERLANDS PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 NETHERLANDS PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 166 NETHERLANDS ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 167 NETHERLANDS MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 168 NETHERLANDS NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 169 NETHERLANDS APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 170 NETHERLANDS CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 171 NETHERLANDS ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 172 NETHERLANDS ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 173 NETHERLANDS EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 174 NETHERLANDS DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 175 NETHERLANDS MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 176 NETHERLANDS AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 177 NETHERLANDS MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 NETHERLANDS MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 179 NETHERLANDS ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 180 NETHERLANDS MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 181 NETHERLANDS MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 182 NETHERLANDS MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 183 NETHERLANDS B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 184 SWITZERLAND MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 185 SWITZERLAND OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 SWITZERLAND OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 187 SWITZERLAND OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 188 SWITZERLAND DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 189 SWITZERLAND MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 SWITZERLAND MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 191 SWITZERLAND MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 192 SWITZERLAND VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 193 SWITZERLAND WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 194 SWITZERLAND GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 195 SWITZERLAND MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 196 SWITZERLAND SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 197 SWITZERLAND MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 198 SWITZERLAND MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 199 SWITZERLAND MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 200 SWITZERLAND PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 201 SWITZERLAND PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 202 SWITZERLAND ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 203 SWITZERLAND MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 204 SWITZERLAND NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 205 SWITZERLAND APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 206 SWITZERLAND CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 207 SWITZERLAND ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 208 SWITZERLAND ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 209 SWITZERLAND EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 210 SWITZERLAND DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 211 SWITZERLAND MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 212 SWITZERLAND AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 213 SWITZERLAND MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 SWITZERLAND MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 215 SWITZERLAND ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 216 SWITZERLAND MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 217 SWITZERLAND MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 218 SWITZERLAND MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 219 SWITZERLAND B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 220 FRANCE MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 221 FRANCE OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 222 FRANCE OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 223 FRANCE OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 224 FRANCE DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 225 FRANCE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 226 FRANCE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 227 FRANCE MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 228 FRANCE VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 229 FRANCE WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 230 FRANCE GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 231 FRANCE MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 232 FRANCE SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 233 FRANCE MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 234 FRANCE MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 235 FRANCE MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 236 FRANCE PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 237 FRANCE PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 238 FRANCE ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 239 FRANCE MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 240 FRANCE NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 241 FRANCE APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 242 FRANCE CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 243 FRANCE ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 244 FRANCE ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 245 FRANCE EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 246 FRANCE DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 247 FRANCE MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 248 FRANCE AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 249 FRANCE MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 250 FRANCE MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 251 FRANCE ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 252 FRANCE MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 253 FRANCE MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 254 FRANCE MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 255 FRANCE B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 256 RUSSIA MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 257 RUSSIA OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 258 RUSSIA OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 259 RUSSIA OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 260 RUSSIA DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 261 RUSSIA MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 262 RUSSIA MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 263 RUSSIA MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 264 RUSSIA VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 265 RUSSIA WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 266 RUSSIA GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 267 RUSSIA MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 268 RUSSIA SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 269 RUSSIA MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 270 RUSSIA MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 271 RUSSIA MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 272 RUSSIA PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 273 RUSSIA PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 274 RUSSIA ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 275 RUSSIA MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 276 RUSSIA NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 277 RUSSIA APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 278 RUSSIA CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 279 RUSSIA ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 280 RUSSIA ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 281 RUSSIA EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 282 RUSSIA DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 283 RUSSIA MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 284 RUSSIA AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 285 RUSSIA MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 286 RUSSIA MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 287 RUSSIA ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 288 RUSSIA MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 289 RUSSIA MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 290 RUSSIA MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 291 RUSSIA B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 292 SPAIN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 293 SPAIN OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 294 SPAIN OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 295 SPAIN OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 296 SPAIN DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 297 SPAIN MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 298 SPAIN MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 299 SPAIN MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 300 SPAIN VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 301 SPAIN WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 302 SPAIN GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 303 SPAIN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 304 SPAIN SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 305 SPAIN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 306 SPAIN MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 307 SPAIN MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 308 SPAIN PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 309 SPAIN PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 310 SPAIN ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 311 SPAIN MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 312 SPAIN NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 313 SPAIN APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 314 SPAIN CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 315 SPAIN ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 316 SPAIN ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 317 SPAIN EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 318 SPAIN DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 319 SPAIN MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 320 SPAIN AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 321 SPAIN MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 322 SPAIN MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 323 SPAIN ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 324 SPAIN MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 325 SPAIN MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 326 SPAIN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 327 SPAIN B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 328 BELGIUM MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 329 BELGIUM OIL IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 330 BELGIUM OIL IN MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 331 BELGIUM OIL IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 332 BELGIUM DRIED MEDICAL CANNABIS IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 333 BELGIUM MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 334 BELGIUM MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY CONCENTRATES, 2020-2029 (USD MILLION)

TABLE 335 BELGIUM MEDICAL CANNABIS CAPSULES IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 336 BELGIUM VAPE PEN IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 337 BELGIUM WHOLE FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 338 BELGIUM GROUND FLOWER IN MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 339 BELGIUM MEDICAL CANNABIS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 340 BELGIUM SYNTHETIC IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 341 BELGIUM MEDICAL CANNABIS MARKET, BY SPECIES, 2020-2029 (USD MILLION)

TABLE 342 BELGIUM MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2029 (USD MILLION)

TABLE 343 BELGIUM MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 344 BELGIUM PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 345 BELGIUM PAIN MANAGEMENT IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 346 BELGIUM ANXIETY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 347 BELGIUM MUSCLE SPASMS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 348 BELGIUM NAUSEA IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 349 BELGIUM APPETITE LOSS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 350 BELGIUM CANCER IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 351 BELGIUM ARTHRITIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 352 BELGIUM ALZHEIMER’S DISEASE/MIGRAINES IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 353 BELGIUM EPILEPSY IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 354 BELGIUM DEPRESSION AND SLEEP DISORDERS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 355 BELGIUM MULTIPLE SCLEROSIS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 356 BELGIUM AUTISM IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 357 BELGIUM MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 358 BELGIUM MENTAL HEALTH CONDITIONS IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 359 BELGIUM ELEVATE MOOD IN MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 360 BELGIUM MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 361 BELGIUM MEDICAL CANNABIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 362 BELGIUM MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 363 BELGIUM B2C IN MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 364 REST OF EUROPE MEDICAL CANNABIS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Europe Medical cannabis Market is to grow at a CAGR of 29.5% during the forecast by 2029.
The significant factors flourishing the growth of the Europe Medical cannabis Market are Rise in Geriatric Population, and Novel Product Development with Increasing Research and Development (R & D) Activities.
The significant factors flourishing the growth of the Europe Medical cannabis Market are Tilray, Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Aurora Cannabis., Elixinol Global Limited, CANOPY GROWTH CORPORATION, Jazz Pharmaceuticals, Inc., ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc.
The major countries covered in the Europe Medical cannabis Market are Germany, France, U.K., Spain, Italy, Netherlands, Belgium, Russia, Switzerland and Rest of Europe.